Feasibility of Clinical Production of Autologous NKG2D CAR-T

The manufacturing approach yielded therapeutic doses of engineered T cells with activity against NKG2D ligands in acute myeloid leukemia and multiple myeloma.

from Latest articles from Cancer Therapy Advisor Hematologic Cancers https://ift.tt/2xkT9IU